Robinhood's tokenized AMC product briefly traded at a significant premium over AMC's actual stock price during the U.S. Labor Day weekend, reaching $18.04 while AMC shares closed at $2.54. This premium occurred when U.S. markets were closed, limiting the usual creation and redemption mechanisms that keep token prices aligned with real shares. The token represents economic exposure but does not grant ownership or voting rights in AMC. The supply of AMC tokens expanded nineteenfold as arbitrageurs created more tokens to capture the premium, which may have led to increased purchases of real AMC shares, though the exact impact on the stock price is unclear. The episode highlights risks and complexities of tokenized stock products, including liquidity gaps during market closures and the need for clearer disclosures. AMC's CEO has opposed the token, but Robinhood maintains the product is legally distinct from actual shares. Regulatory and legal outcomes remain uncertain.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
